Development of an aptamer-based Adjunctive Blood Detoxification (ABD) medical device indicated to use in Chronic Kindney Diesease (CKD) for targeted removal of uremic toxins from pantients’ blood.
Within the non-systemic therapies segment, Pure Biologics uses aptamers to create innovative therapeutic solutions – adsorbers that selectively remove pathogenic molecules from patients’ blood for nephrology applications. We have a proprietary, patented PureApta technology platform for aptamer selection and are one of the few companies worldwide developing aptamers for therapeutic purposes. As aptamers are a relatively young class of drugs, we are also conducting internal technology projects, including research on improving aptamer stability and safety studies of modified nucleotides.
Extracorporeal therapy projects are being carried out by a company founded as a subsidiary of Pure Biologics:
